Bernard A. Fox

@bernardafox.bsky.social

Cancer Immunotherapy & Harder Family Chair Cancer Research #FoxLab @ChilesResearch /CEO @UbiVac / @OHSUmmi.bsky.social /exPres&Ambassador @SITCancer.bsky.social /ex #NCI /ex #Detroit /M GO BLUE/ WIC & JEDI/ @detroitlions.bsky.social /❤️Pinot/Tweets my own

Dr. @ertrunnell.bsky.social thanks for posting. While there is much yet to do, think in not too distant future #GigaTIME will have a major impact in tailoring therapies to patients with #cancer #GSK #Astrazeneca #Regeneron #Abbvie #incyte #FDA #NCI #FinishCancer

Emily R. Trunnell, Ph.D.@ertrunnell.bsky.social · 8mo ago

Led by @hoifungpoon.bsky.social & @shengwanguw.bsky.social, @chanwoo-kim.bsky.social, @bernardafox.bsky.social et al. conducted the first-ever population-scale study of the tumor immune microenvironment based on spatial #proteomics. In @cp-cellstemcell.bsky.social: www.cell.com/cell/fulltex...

4 decades of IO – Celebrating 40 years of SITC. In 2020, our membership surpassed 4,000 members as we launched two programs: the Certificate in Cancer Immunotherapy and Global Access to Immunotherapy. Our Annual Meeting was held fully virtual due to the COVID-19 pandemic.

Bild

4 decades of IO – Celebrating 40 years of SITC. In 2024, we published “Challenges and opportunities in cancer immunotherapy: a SITC strategic vision”. We also announced a vision for 100 novel IO agents to be approved by 2034 with IO Drug Development Summit in Boston, MA

Bild